Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Shares Issued (2017 - 2025)

Voyager Therapeutics (VYGR) has disclosed Shares Issued for 9 consecutive years, with $303000.0 as the latest value for Q4 2025.

  • Quarterly Shares Issued rose 138.58% to $303000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $549000.0 through Dec 2025, up 41.49% year-over-year, with the annual reading at $549000.0 for FY2025, 41.49% up from the prior year.
  • Shares Issued hit $303000.0 in Q4 2025 for Voyager Therapeutics, up from $85000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $1.2 million in Q2 2023 to a low of -$355000.0 in Q3 2022.
  • Historically, Shares Issued has averaged $194000.0 across 5 years, with a median of $90000.0 in 2024.
  • Biggest five-year swings in Shares Issued: skyrocketed 1441.67% in 2023 and later plummeted 92.68% in 2024.
  • Year by year, Shares Issued stood at $28000.0 in 2021, then surged by 789.29% to $249000.0 in 2022, then tumbled by 90.76% to $23000.0 in 2023, then soared by 452.17% to $127000.0 in 2024, then surged by 138.58% to $303000.0 in 2025.
  • Business Quant data shows Shares Issued for VYGR at $303000.0 in Q4 2025, $85000.0 in Q3 2025, and $79000.0 in Q2 2025.